Assessing the Ideal Environments in Which Psychedelic Medicines Should Be Administered
December 27th 2021Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which environments each psychedelic medicine is likely to be administered.
Expert: NIH Encourages Data from Clinical Trials be Disaggregated by Sex in Reporting
December 24th 2021Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health, discusses how clinical trials have evolved to address biological and sociological variables in patient health.
How Trial Results Assessing Dara-KRd in Multiple Myeloma May Impact the Treatment Landscape
December 24th 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.
The Psychedelic Drugs Currently Under Investigation for Potential FDA Approval
December 24th 2021Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.
Expert: US Drug Shortages May Not Be Associated With Problems in the Global Supply Chain
December 24th 2021Andrew Mulcahy, PhD, a senior policy researcher at RAND Corporation, discusses a recent report that showed the drug shortages in the United States may not be associated with problems in the global supply chain.
Expert: 'We Cannot Overstate or Ignore' Relationship Between Diabetes, COVID-19 Infection Risk
December 24th 2021Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses how the diabetes DRIVE program compares with the SHC DRIVE models for flu and COVID-19 vaccinations.
Adverse Events in Trial Assessing Dara-KRd in Patients With Newly Diagnosed Multiple Myeloma
December 23rd 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.
Next Steps in Assessing BOVen Therapy in Patients With Previously Untreated CLL
December 23rd 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Expert: Pharmacists, USP Worked Together ‘A Hundred Times Faster Than Ever Before’ in 2021
December 22nd 2021Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.
Assessing Trial Results for All Endpoints for Dara-KRd in Treatment of Multiple Myeloma
December 22nd 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the results for all of the trial endpoints assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma.
Safety, Efficacy of BOVen Therapy in Patients With Previously Untreated CLL
December 22nd 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Assessing the Primary Endpoint Trial Results for Dara-KRd in Treatment of Multiple Myeloma
December 21st 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the primary endpoint in the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.
Assessing Adverse Events From BOVen Therapy in Patients With Previously Untreated CLL
December 21st 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.
Expert: USP, Pharmacy Came Together in 2021 to Create Vaccine Toolkits ‘For Every Vaccine Created’
December 20th 2021Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses what stands out as the biggest challenge from the past year and what role USP and pharmacists had in overcoming that challenge.
Safety, Efficacy of Dara-KRd in Treatment of Patients With Newly Diagnosed Multiple Myeloma
December 20th 2021Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on the safety and efficacy of Dara-KRd in the treatment of patients with newly diagnosed multiple myeloma.
Assessing Primary Endpoint Trial Results for BOVen Therapy in Previously Untreated CLL
December 20th 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, addresses the primary endpoint in the trial assessing zanubrutinib, obinutuzumab, and venetoclax in previously untreated chronic lymphocytic leukemia.
Expert: The NIH ORWH Ensures ‘Women's Health Research Is Part of the Scientific Framework of NIH’
December 20th 2021Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses how the work of the NIH ORWH impacts pharmacy practice.